UY28823A1 - Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1 - Google Patents

Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1

Info

Publication number
UY28823A1
UY28823A1 UY28823A UY28823A UY28823A1 UY 28823 A1 UY28823 A1 UY 28823A1 UY 28823 A UY28823 A UY 28823A UY 28823 A UY28823 A UY 28823A UY 28823 A1 UY28823 A1 UY 28823A1
Authority
UY
Uruguay
Prior art keywords
heteroaril
anrl
aril
alpha
propanoic acid
Prior art date
Application number
UY28823A
Other languages
English (en)
Inventor
Yoshinobu Hashizume
Masako Hirota
Sachiko Mihara
Hiroshi Nakamura
Hiroki Koike
Yukari Matsumoto
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY28823A1 publication Critical patent/UY28823A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Esta invención proporciona los compuestos de fórmula (I): o un éster farmacéuticamente aceptable de tal compuesto, o una sal farmacéuticamente aceptable del mismo, donde R1 y R2 representan independientemente un átomo de hidrógeno o similar; R3 representa un grupo arilo que tiene de 6 a 10 átomos en el anillo o similar; X representa un átomo de oxígeno o similar; Y representa un átomo de oxígeno o similar; y n representa un número entero 0, 1 ó 2. Estos compuestos tienen actividad antagonista del receptor ORL1; y, por lo tanto, son útiles para tratar enfermedades o afecciones tales como dolor, diversas enfermedades del SNC etc.
UY28823A 2004-03-29 2005-03-29 Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1 UY28823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55759804P 2004-03-29 2004-03-29

Publications (1)

Publication Number Publication Date
UY28823A1 true UY28823A1 (es) 2005-10-31

Family

ID=34961283

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28823A UY28823A1 (es) 2004-03-29 2005-03-29 Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1

Country Status (13)

Country Link
US (2) US7354925B2 (es)
EP (2) EP1732928A2 (es)
JP (2) JP2007530653A (es)
AR (1) AR048340A1 (es)
BR (2) BRPI0509377A (es)
CA (2) CA2561488A1 (es)
DO (1) DOP2005000046A (es)
MX (1) MXPA06011265A (es)
NL (1) NL1028624C2 (es)
PA (1) PA8627801A1 (es)
TW (1) TW200533641A (es)
UY (1) UY28823A1 (es)
WO (2) WO2005092895A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (en) 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
SE0303090D0 (sv) 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
US7354925B2 (en) * 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
BRPI0607402A2 (pt) * 2005-03-01 2009-09-01 Pfizer Ltd uso de inibidores de pde7 para o tratamento de dor neuropática
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
JP2008543826A (ja) * 2005-06-17 2008-12-04 ファイザー株式会社 ＯＲＬ１−受容体アンタゴニストとしてのα−（アリール−またはヘテロアリール−メチル）−β−ピペリジノプロパン酸化合物
WO2007057775A1 (en) * 2005-11-21 2007-05-24 Pfizer Limited Spiropiperidine derivatives
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
CL2007002950A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Uso de compuestos derivados de espiro-oxindol en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer
US7470684B2 (en) 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
EP2733145A1 (en) 2009-10-14 2014-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
KR101368130B1 (ko) * 2009-11-16 2014-02-27 일라이 릴리 앤드 캄파니 Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물
UA107943C2 (en) * 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
TW201643169A (zh) * 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
WO2012074721A2 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of serotonin receptor antagonists by microinjection systems
EA025500B1 (ru) * 2012-02-03 2016-12-30 Грюненталь Гмбх (1R,4R)-6'-ФТОР-(N-МЕТИЛ- ИЛИ N,N-ДИМЕТИЛ-)-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН ДЛЯ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ И СИНДРОМА ХРОНИЧЕСКОЙ УСТАЛОСТИ
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CA3006966A1 (en) * 2015-12-02 2017-06-08 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
TW202140480A (zh) * 2020-01-15 2021-11-01 日商拉夸里亞創藥股份有限公司 作為crhr2拮抗劑之螺雜環衍生物
WO2023284833A1 (zh) * 2021-07-14 2023-01-19 宜昌人福药业有限责任公司 一种螺哌啶环衍生物及其药物组合物、制备方法和用途
CN114436996B (zh) * 2021-12-31 2024-05-10 华中科技大学 一种β2-氨基酸衍生物的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5206240A (en) 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
CA2163995A1 (en) 1993-06-07 1994-12-22 Malcolm Maccoss Spiro-substituted azacycles as neurokinin antagonists
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU2001288110A1 (en) 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds
JP2002173485A (ja) 2000-09-27 2002-06-21 Takeda Chem Ind Ltd スピロ化合物
DK1385514T5 (da) 2001-04-18 2009-03-09 Euro Celtique Sa Spiroinden- og spiroindanforbindelser
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
WO2003064425A1 (en) * 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
EP1532147B1 (en) 2002-06-27 2006-08-02 Schering Corporation Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
WO2004041279A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US7354925B2 (en) * 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists

Also Published As

Publication number Publication date
PA8627801A1 (es) 2006-05-16
WO2005092895A2 (en) 2005-10-06
MXPA06011265A (es) 2006-12-15
BRPI0509307A (pt) 2007-09-04
EP1732893A2 (en) 2006-12-20
US7354925B2 (en) 2008-04-08
WO2005092895A3 (en) 2006-03-02
NL1028624C2 (nl) 2006-02-21
US20070197500A1 (en) 2007-08-23
JP2007530656A (ja) 2007-11-01
WO2005092858A2 (en) 2005-10-06
CA2563164A1 (en) 2005-10-06
WO2005092858A3 (en) 2006-03-02
EP1732928A2 (en) 2006-12-20
US7279486B2 (en) 2007-10-09
US20050277659A1 (en) 2005-12-15
BRPI0509377A (pt) 2007-09-11
CA2561488A1 (en) 2005-10-06
DOP2005000046A (es) 2005-11-30
AR048340A1 (es) 2006-04-19
TW200533641A (en) 2005-10-16
JP2007530653A (ja) 2007-11-01
NL1028624A1 (nl) 2005-10-03

Similar Documents

Publication Publication Date Title
UY28823A1 (es) Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ECSP066966A (es) Compuestos de aril-o heteroarilamida ortosustituidos
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
PA8610801A1 (es) Compuestos de aril o heteroaril amida
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
UY26872A1 (es) Derivados de la 4- fenil piridina
NO20080391L (no) Pyrazolbaserte LXR modulatorer
UA92083C2 (ru) Азабициклические алкановые производные, замещенные конденсированным бициклогетероциклом
DOP2010000046A (es) Compuestos de biciclolactama sustituida
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas
UY26729A1 (es) Alquilaminas heterocíclicas como antagonistas de los receptores muscarínicos
SE0200919D0 (sv) Chemical compounds
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR041864A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
AR053560A1 (es) Compuestos antibacterianos de 3,3' dialcoxi-2,2' -dihidroxi -1,1' -bifenilo 5,5' disustituidos y metodos relacionados
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
NO20080285L (no) Alfa-(aryl- eller heteroarylmetyl)-beta-piperidinopropionsyreforbindelser som ORL-1-reseptorantagonist
DOP2002000518A (es) Compuestos azapoliciclicos condensados con arilo

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20131204